RIPK1 Inhibitor Compounds Modulating Inflammatory Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic inflammation and dysregulation of receptor-interacting protein kinase 1 (RIPK1) signaling lead to excessive inflammation and cell death, contributing to various human diseases, for which current therapies are inadequate.
Innovation Solution
Development of compounds that inhibit RIPK1, including specific pharmaceutical compositions and methods for their synthesis and administration, to treat RIPK1-mediated diseases by modulating inflammatory responses and cell death pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat RIPK1-mediated diseases, then treatment is provided, but therapeutic effectiveness is inadequate
Solution Approach 1:
The patent modifies the chemical structure of RIPK1 inhibitors by changing parameters such as substituting hydrogen atoms with deuterium atoms, adjusting molecular weight, and modifying functional groups. These parameter changes enhance the binding affinity and selectivity of the inhibitors toward RIPK1, thereby improving therapeutic effectiveness while reducing excessive inflammation and cell death.
Solution Approach 2:
The patent employs composite molecular structures that combine multiple functional moieties within a single inhibitor compound. These composite structures enable simultaneous interaction with multiple binding sites on RIPK1, enhancing inhibitory potency and providing broader therapeutic benefits for treating RIPK1-mediated diseases.
2Object-generated harmful factors
If RIPK1 signaling is inhibited, then excessive inflammation and cell death are reduced, but new compounds must be developed and synthesized
Solution Approach 1:
The patent divides the complex task of inhibitor development into systematic segments: identifying key binding residues, designing modular molecular frameworks, synthesizing core compounds, and optimizing specific functional groups. This segmentation allows for efficient exploration of the chemical space and reduces the overall complexity of developing new RIPK1 inhibitors.
Solution Approach 2:
The patent utilizes parameter changes such as deuterium substitution and molecular weight adjustment to optimize compound properties. By systematically varying these parameters across a series of compounds, the patent identifies optimal inhibitors with enhanced binding affinity and selectivity, reducing the need for exhaustive screening of vast chemical libraries.
3Productivity
If compound synthesis methods are developed, then new inhibitors can be produced, but manufacturing processes become more complex
Solution Approach 1:
The patent employs preliminary action by establishing convergent synthesis routes and pre-assembling molecular fragments before final assembly. This approach allows for the efficient production of multiple inhibitors from common intermediates, increasing productivity while managing synthesis complexity through standardized protocols and modular building blocks.
Data Source
AI summary
The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.